Details

Autor(en) / Beteiligte

• KAWAKAMI, YOSHIKAZU
• ABE, SHOSAKU
• OHMICHI, MITSUHIDE
• INOUE, HIROSHI
• YOSHIDA, MASAMI
• KOBAYASHI, HITOSHI
• ITO, TAKASHI
• BANDO, TAKESHI
• TAKEUCHI, KENICHI
• HIRANO, HARUTO
• TANNO, YASUO
• SAKAMOTO, MASAHIRO
• NUKIWA, TOSHIHIRO
• YANASE, KENJI
• ITO, NOBUO
• FUKUDA, KIYOSHI
• KOBA, HIROYUKIYASHI
• WATANABE, HIDEHIRO
• INAMATSU, TAKASHI
• SANO, YASUYUKI
• KURAKI, TAKASHIGE
• SHISHIDO, HARUMI
• TANOUE, SHOKO
• KOYAMA, MASARU
• KUDO, KOICHIRO
• KOSHINO, TAKESHI
• OKUBO, TAKAO
• TANI, KENJI
• SHOJI, AKIRA
• CHIBA, JUN
• IKEHARA, KUNIHIKO
• SAKURAI, IWAO
• TAKAHASHI, HIROSHI
• ARAKAWA, MASAAKI
• WADA, KOICHI
• IWATA, FUMIHIDE
• TSUKADA, HIROKI
• SUZUKI, YASUTOSHI
• SATO, ATSUHIKO
• IWATA, MASATOSHI
• SHICHI, IZUMI
• YASUDA, KAZUMASA
• TAKAGI, KENZO
• WATANABE, YOSHIAKI
• TANIGUCHI, HIROYUKI
• USUI, ISAO
• BANDO, KENJI
• KISHIMOTO, TADAMITSU
• IKEDA, AKINORI
• OKUMOTO, TAKESHI
• MIKI, FUMIO
• OKAWA, KENTARO
• MIKASA, KEIICHI
• HIGASHINO, KAZUYA
• MAEBO, AKIO
• NOMURA, SHIGEO
• YAMAGUCHI, KAZUYUKI
• HIRABAYASHI, MASATAKA
• YOSHIDA, MASAO
• MATSUSHIMA, TOSHIHARU
• MATSUMOTO, YUKIO
• ISHIOKA, SHINICHI
• KUWAHARA, MASAO
• MOCHIZUKI, NOBUHIRO
• YANAGIDA, JITSURO
• ARITA, KENICHI
• DAIDO, KAZUHIRO
• EJIMA, TSUYOSHI
• MIKI, SATOSHI
• SAWAE, YOSHIRO
• YOSHIDA, MINORU
• SHIRAISHI, TSUNEAKI
• KAWAHARA, MASASHI
• KAWAYAMA, TOMOTAKA
• HONDA, YOSHIAKI
• ISHIBASHI, TSUNEO
• TAKAMOTO, MASAHIRO
• KAJIKI, AKIRA
• FUJISAWA, NOBUMITSU
• SUGA, MORITAKA
• DOI, TOSHINORI
• TAKENAKA, SHINOBU
• HARA, KOHEI
• KOHNO, SHIGERU
• KAKU, MITSUO
• INOUE, YUICHI
• YAMASHITA, YUKO
• SAKATA, SHINGO
• FUJII, TAKESHI
• IRIFUNE, KENJI
• MIYAZAKI, YOSHITSUGU
• WATANABE, TAKASHI
• MATSUMOTO, KEIZO
• AKIYAMA, MORITOSHI
• NAKAMA, KAORU
• MATSUKURA, SHIGERU
• MASHIMOTO, HIDEO
• MUKAE, HIROSHI
• DEGUCHI, KOICHI
• NAKASHIMA, MITSUYOSHI

Titel

COMPARATIVE STUDY ON THE EFFICACY OF RITIPENEM ACOXIL AND CEFOTIAM HEXETIL IN CHRONIC LOWER RESPIRATORY TRACT INFECTIONS BY THE DOUBLE-BLIND METHOD

Ist Teil von

• The Japanese Journal of Antibiotics, 1996/03/25, Vol.49(3), pp.219-249

Ort / Verlag

Japan: Japan Antibiotics Research Association

Erscheinungsjahr

1996

Link zum Volltext

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against chronic lower respiratory tract infections, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as a control drug. RIPM-AC was orally administered at 200 mg, and CTM-HE at 400 mg, t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrol led in this trial was 202, of which 151 cases (RIPM-AC group: 75, CTM-HE group: 76) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent+good) were 85.3% (64/75) in the RIPM-AC group and 80.3% (61/76) in the CTM-HE group. There was no significant difference between the two groups, hence the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 50.0% (13/26) in the RIPM-AC group and 75.0% (18/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 10 cases (11.0%) of the RIPM-AC group and 10 cases (10.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 8 cases(9.5%) of the RIPM-AC group and in 14 cases (16.7%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects and abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 73 cases (80.2%) and CTM-HE in 71 cases (77.2%), with no significant difference. 4. The usefulness rates (markedly useful+useful) were 79.5% (62/78) in the RIPM-AC group and 76.9% (60/78) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of chronic lower respiratory tract infCctions.